Document is current
Any future updates will be listed below
-
Authors
Blin, Patrick https://orcid.org/0000-0003-4005-7928
Joubert, Michael https://orcid.org/0000-0002-8731-7355
Jourdain, Patrick https://orcid.org/0000-0002-5202-6902
Zaoui, Philippe https://orcid.org/0000-0001-5332-1586
Guiard, Estelle https://orcid.org/0000-0001-5851-3288
Sakr, Dunia
Dureau-Pournin, Caroline https://orcid.org/0000-0002-3643-683X
Bernard, Marie-Agnès
Lassalle, Régis https://orcid.org/0000-0001-6726-6215
Thomas-Delecourt, Florence
Bineau, Sébastien
Moore, Nicholas https://orcid.org/0000-0003-1212-2817
Droz-Perroteau, Cécile https://orcid.org/0000-0002-7697-1167
-
Funding
Funding for this research was provided by:
Astra-Zeneca, France
- License Information
-
More Information
Article History
Received: 3 October 2023
Accepted: 22 December 2023
First Online: 9 January 2024
Declarations
:
: SNDS is a pseudonymized database and no individual patient consent was required. The study complied with all regulations including GDPR. It received a positive approval from the CEREES (Expert Committee on Health Research, Studies and Evaluations) and the authorization from the CNIL (Commission Nationale de l’Informatique et des Libertés), the French data protection authority.
: The manuscript contains no individual data.
: PB, EG, DS, CaDP, MAB, RL, NM, CeDP are employed of the Bordeaux PharmacoEpi and do not benefit personally from this funding, except some of their salary during the study period, FTD and SB are employed of AstraZeneca, MJ, PJ and PZ are clinician experts and received fees for their participation to the scientific committee of the study.
